The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or ...

On Tuesday, the FDA approved NovoCure’s (NASDAQ:NVCR) Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer (mNSCLC) who ...

Optune Lua received a CE Mark for treating metastatic NSCLC, used with immune checkpoint inhibitors or docetaxel after progression on a platinum-based regimen. The phase 3 LUNAR trial showed ...

Whether you are a working professional, a high school graduate or an academician, the need for PDF is indispensable. This excellent document format makes sharing files easy in a compact way. Further, ...

Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE Mark ...

「Lua Development Tools（LDT）」は、スクリプト言語“Lua”によるプログラミングが可能な「Eclipse」ベースの統合開発環境。32bit版および64bit版のWindowsなどに対応するフリーソフトで、“eclipse.org”のWebサイトからダウンロードできる。なお、動作にはJavaラン ...

Lua, the mobile first communications platform for any workforce, has today launched a brand new feature of the product called Insights. Insights is a metrics platform that will allow clients to see in ...